JS6 free base · Synonyms: CPDP801685

JS6 is a Bcl3 inhibitor.

For research use only. Not for human or veterinary use.

Target NF-κB

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

JS6 structure

CAS No.: 950244-33-4

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
100 mg	USD 465.00	BP-02112-100mg	In stock	Get quote
250 mg	USD 765.00	BP-02112-250mg	In stock	Get quote
500 mg	USD 1,165.00	BP-02112-500mg	In stock	Get quote
1 g	Inquire	BP-02112-1g	Inquire	Inquire

Need another size or custom synthesis? Request a quote.

Description

JS6 is a Bcl3 inhibitor, and inhibits Bcl3-NF-kB1 binding. JS6 inhibits tumor cell growth in vitro and in vivo.

Biological activity

In Vitro JS6 potently inhibits Bcl3 activity in cancer cells, reducing Bcl3-NF-κB1 binding, tumor colony formation, and cancer cell migration[1]. JS6 (Compound 1a) (24 h) reduces the viability of MCF-10A, MDA-MB-231 and SKBR3 breast cancer cells[2]. JS6 (24 h pre-incubation followed by 24 h chamber incubation) reduces the motility of MDA-MB-231 cells overexpressing Bcl-3[2]. JS6 (24 h) inhibits the binding of Bcl-3 to p50 in HEK-293 cells overexpressing FLAG-tagged Bcl-3[2]. JS6 (pre-incubated for 24 h, followed by 48 h of incubation after transfection) inhibits the NF-κB signaling pathway in Bcl-3-overexpressing MDA-MB-231 cells, Bcl-3-overexpressing HEK-293 cells, and HEK-293 cells overexpressing both Bcl-3 and p52[2].

Identifiers

SMILES: O=C(NCCN1CCOCC1)C2=CC=CC=C2NC(C3=CC=CC=C3F)=O
InChIKey: QEEPXSHOUBCRGQ-UHFFFAOYSA-N

Specifications

MW (average): 371.4054
Formula: C₂₀H₂₂FN₃O₃
CAS No.: 950244-33-4
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month.

Solubility

Soluble in DMSO : 50 mg/mL

Documents

References

[1]. Soukupová J, et al. The Discovery of a Novel Antimetastatic Bcl3 Inhibitor. Mol Cancer Ther. 2021;20(5):775-786.

[2]. Westwell, A. D. (2015). 2‑Benzoylaminobenzamide derivatives as BCL‑3 inhibitors (PCT Patent No. WO2015014972A1). WIPO.

Same target

Search NF-κB

Same research area

Search Cancer